EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

ANO1‐Mediated Inhibition of Cancer Ferroptosis Confers Immunotherapeutic Resistance through Recruiting Cancer‐Associated Fibroblasts

Fangli Jiang, Keren Jia, Yang Chen, Congcong Ji, Xiaoyi Chong, Zhongwu Li, Feilong Zhao, Yuezong Bai, Sai Ge, Jing Gao, Xiaotian Zhang, Jian Li und 2 weitere

Advanced Science · 2023

DOI: 10.1002/advs.202300881 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2023. Verfasst von Fangli Jiang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking Universi…. Hauptthemen laut MEDLINE: Ferroptosis, Cancer-Associated Fibroblasts, Gastrointestinal Neoplasms. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Clinical Medicine Plus X-Young Scholars Project, Peking University, the Fundamental Research Funds for the Central Universities, Science Foundation of Peking University Cancer Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The application of immunotherapy in gastrointestinal (GI) cancers remains challenging because of the limited response rate and emerging therapeutic resistance. Combining clinical cohorts, multi‐omics study, and functional/molecular experiments, it is found that ANO1 amplification or high‐expression predicts poor outcomes and resistance to immunotherapy for GI cancer patients. Knocking‐down or inhibiting ANO1 suppresses the growth/metastasis/invasion of multiple GI cancer cell lines, cell‐derived xenograft, and patient‐derived xenograft models. ANO1 contributes to an immune‐suppressive tumor microenvironment and induces acquired resistance to anti‐PD‐1 immunotherapy, while ANO1 knockdown or inhibition enhances immunotherapeutic effectiveness and overcomes resistance to immunotherapy. Mechanistically, through inhibiting cancer ferroptosis in a PI3K‐Akt signaling‐dependent manner, ANO1 enhances tumor progression and facilitates cancer‐associated fibroblast recruitment by promoting TGF‐ β release, thus crippling CD8 + T cell‐mediated anti‐tumor immunity and generating resistance to immunotherapy. This work highlights ANO1's role in mediating tumor immune microenvironment remodeling and immunotherapeutic resistance, and introduces ANO1 as a promising target for GI cancers’ precision treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FerroptosisCancer-Associated FibroblastsGastrointestinal NeoplasmsHumansPhosphatidylinositol 3-KinasesCell ProliferationNeoplasm ProteinsImmunotherapyTumor MicroenvironmentAnoctamin-1

Stichwörter der Autor:innen

ANO1cancer-associated fibroblastsferroptosisgastrointestinal cancersimmunotherapeutic resistance

Substanzen

Phosphatidylinositol 3-KinasesNeoplasm ProteinsANO1 protein, humanAnoctamin-1

Autor:innen und Institutionen

  • Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing, 100142, P. R. China.
  • Department of Pathology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing, 100142, P. R. China.
  • Department of Medical Affairs, 3D Medicines, Inc., Shanghai, 201199, P. R. China.
  • Department of Oncology, Shenzhen Key Laboratory of Gastrointestinal Cancer Translational Research, Cancer Institute, Peking University Shenzhen Hospital, Shenzhen-Peking University-Hong Kong University of Science and Te…

ORCID-Profile: Cheng Zhang

Förderung

  • National Natural Science Foundation of China
  • Clinical Medicine Plus X-Young Scholars Project, Peking University, the Fundamental Research Funds for the Central Universities
  • Science Foundation of Peking University Cancer Hospital
  • Xisike-leader Oncology Research Foundation
  • Beijing Hospitals Authority Youth Programme

Zitieren

APA

Jiang, F., Jia, K., Chen, Y., Ji, C., Chong, X., Li, Z., Zhao, F., Bai, Y., Ge, S., Gao, J., Zhang, X., Li, J., Shen, L., & Zhang, C. (2023). ANO1‐Mediated Inhibition of Cancer Ferroptosis Confers Immunotherapeutic Resistance through Recruiting Cancer‐Associated Fibroblasts. Advanced Science. https://doi.org/10.1002/advs.202300881

Vancouver

Jiang F, Jia K, Chen Y, Ji C, Chong X, Li Z, et al. ANO1‐Mediated Inhibition of Cancer Ferroptosis Confers Immunotherapeutic Resistance through Recruiting Cancer‐Associated Fibroblasts. Advanced Science. 2023. doi:10.1002/advs.202300881

BibTeX
@article{Jiang2023,
  author = {Jiang, Fangli and Jia, Keren and Chen, Yang and Ji, Congcong and Chong, Xiaoyi and Li, Zhongwu and Zhao, Feilong and Bai, Yuezong and Ge, Sai and Gao, Jing and Zhang, Xiaotian and Li, Jian and Shen, Lin and Zhang, Cheng},
  title = {ANO1‐Mediated Inhibition of Cancer Ferroptosis Confers Immunotherapeutic Resistance through Recruiting Cancer‐Associated Fibroblasts},
  journal = {Advanced Science},
  year = {2023},
  doi = {10.1002/advs.202300881}
}
Kostenlos starten →